CORE C (Biostatistics) will reside within the University of Pittsburgh Cancer Institute's (UPCl) Biostatistics Facility, which provides clinical and basic-science investigators in UPCl with statistical expertise in design, analysis, and reporting of cancer-related research studies. These cover basic-science studies;phase I and phase II oncology clinical trials;epidemiologic studies, including those related to cancer prevention and awareness;and investigations of behavioral and health sequelae of cancer treatment. In its role as Core C for this SPORE, the Biostatistics Core will support all four research projects. We will collaborate with investigators on statistical aspects of the design of in vitro and in vivo laboratory-based studies as new data come to light, and perform both exploratory and confirmatory statistical analyses of the resulting data from key experiments in Projects 1-4. We will perform interim analyses of safety for the SPORE's clinical trials (Projects 2, 3, &4), and final analyses of their data on safety, immune response, and treatment efficacy. We will contribute to the review of the SPORE's developmental research-program proposals, and provide statistical support to those that are funded. We will provide statistical support to the career-development awardees. We will work with the project investigators, with Core D (Informatics), and with UPCl Clinical Research Services, a component of Core A, to ensure that the requisite laboratory and clinical-trial data are available for statistical analyses. We will collaborate with the project investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations. We will also conduct methodological research motivated by the SPORE projects to improve the statistical efficiency in the study design and analysis.
Members of the biostatistics core have considerable statistical expertise and experiences in the design and analysis of both laboratory and clinical data. We have long standing collaboration history with the investigators of the Melanoma program in UPCl and have worked closely with the SPORE investigators during the last funding period. We will provide integrated support for the design and analysis of all SPORE studies in the next funding period of the SPORE.
|Dulmage, B O; Feng, H; Mirvish, E et al. (2015) Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol 172:1449-51|
|Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFR? up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41|
|Tarhini, Ahmad A; Edington, Howard; Butterfield, Lisa H et al. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705|
|Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18|
|Tarhini, Ahmad A; Shin, Donghoon; Lee, Sandra J et al. (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 24:150-7|
|Pancoska, Petr; Kirkwood, John M; Bouros, Spyros et al. (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375|
|Tarhini, Ahmad A; Lin, Yan; Yeku, Oladapo et al. (2014) A four-marker signature of TNF-RII, TGF-?, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 12:19|
|Geskin, Larisa J; Akilov, Oleg E; Lin, Yan et al. (2014) Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 23:598-600|
|Schowalter, Michael K; Dulmage, Brittany O; Ho, Jonhan et al. (2014) Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res 24:397-400|
|McArthur, Grant A; Chapman, Paul B; Robert, Caroline et al. (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-32|
Showing the most recent 10 out of 59 publications